ImmunityBio’s stock continued its upward trajectory following a series of significant announcements, capping a month marked by regulatory wins and substantial revenue growth. The latest surge was triggered by a key development in the company’s cell therapy platform.
Manufacturing and Clinical Milestones Achieved
The biotechnology firm announced the successful completion of two critical manufacturing programs on Friday. These programs are centered on establishing a safe and scalable production process for its proprietary cell therapy platform. In a related Phase I study involving 74 participants, the infusions, particularly when combined with its flagship product, ANKTIVA, demonstrated a favorable safety and tolerability profile.
Further validating the platform’s potential, researchers from the National Cancer Institute presented new data at a recent scientific conference. In preclinical models for lung cancer, the combination therapy resulted in a statistically significant reduction in tumor volume. Investors responded positively to this news, driving the share price up by over nine percent.
Revenue Surge and Global Rollout Amid Financial Challenges
This latest price increase is part of a broader rally. The stock had already jumped eleven percent following the release of its most recent quarterly results, which were highlighted by a dramatic revenue leap. Full-year 2025 sales for ANKTIVA soared by approximately 700 percent to $113 million.
Should investors sell immediately? Or is it worth buying ImmunityBio?
Concurrently, ImmunityBio is rapidly advancing its global commercialization efforts. The European Commission recently granted a conditional marketing authorization for certain bladder cancer patients. The company is also poised for expansion in the Middle East, specifically Saudi Arabia, following a new distribution partnership. In the United States, the Food and Drug Administration (FDA) is reviewing a new application for an expanded indication that could address roughly 70 percent of annual U.S. cases.
Despite these commercial strides, the company’s financial picture remains challenging. An EBIT margin of negative 278 percent underscores that profitability is not yet on the immediate horizon. Continued heavy investment in research and development is reflected in a negative free cash flow of nearly $72 million.
Upcoming Catalysts and Financial Runway
The calendar for the coming months features several pivotal events. A key meeting with the FDA is scheduled for March to clarify the regulatory pathway for the recombinant BCG program. Furthermore, management plans to submit another marketing application for untreated bladder cancer patients in the fourth quarter of 2026. With $242 million in liquid assets, the near-term financing for these initiatives appears secure.
Ad
ImmunityBio Stock: Buy or Sell?! New ImmunityBio Analysis from March 15 delivers the answer:
The latest ImmunityBio figures speak for themselves: Urgent action needed for ImmunityBio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 15.
ImmunityBio: Buy or sell? Read more here...
